Theravance Biopharma (TBPH) News Today $16.37 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$16.38 +0.01 (+0.06%) As of 05/22/2026 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TBPH Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period Wall Street Zen Downgrades Theravance Biopharma (NASDAQ:TBPH) to HoldMay 16, 2026 | americanbankingnews.comTheravance Biopharma (NASDAQ:TBPH) Releases Quarterly Earnings Results, Misses Estimates By $0.13 EPSMay 9, 2026 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHMay 7, 2026 | prnewswire.comTheravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 7, 2026 | prnewswire.comTheravance Biopharma (TBPH) Projected to Post Earnings on ThursdayMay 7, 2026 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Lowered to "Buy" Rating by Wall Street ZenMay 2, 2026 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHApril 30, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHApril 28, 2026 | globenewswire.comLaughing Water Capital’s New Position: Theravance Biopharma, Inc. (TBPH)April 25, 2026 | insidermonkey.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Rating of "Moderate Buy" by BrokeragesApril 25, 2026 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHApril 21, 2026 | globenewswire.comB. Riley Lifts PT on Theravance Biopharma (TBPH) to $17 From $14April 20, 2026 | insidermonkey.com8 Most Undervalued Biotech Stocks to Buy Right NowApril 18, 2026 | insidermonkey.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHApril 16, 2026 | prnewswire.comTBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP InvestigatesApril 15, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHApril 14, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Theravance Biopharma (TBPH)April 10, 2026 | theglobeandmail.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHApril 9, 2026 | prnewswire.comTBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law FirmApril 2, 2026 | businesswire.comTBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP InvestigatesApril 1, 2026 | prnewswire.comTheravance Biopharma (TBPH) price target decreased by 39.48% to 16.49March 27, 2026 | msn.comTBPH Guided for $75M in Milestones While Trial Risk Went Unquantified -- LEVI & KORSINSKY, LLPMarch 26, 2026 | globenewswire.comTBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP InvestigatesMarch 25, 2026 | prnewswire.comTheravance Bio: Q4 Earnings SnapshotMarch 19, 2026 | sfgate.comTheravance Biopharma (NASDAQ:TBPH) SVP Rhonda Farnum Sells 31,067 Shares of StockMarch 19, 2026 | insidertrades.comTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateMarch 19, 2026 | prnewswire.comTBPH Guided for $75M in Milestones While Trial Risk Went Unquantified -- LEVI & KORSINSKY, LLPMarch 18, 2026 | prnewswire.comHow The Theravance Biopharma (TBPH) Story Is Reset Around Respiratory Assets And CashMarch 11, 2026 | finance.yahoo.comTBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP InvestigatesMarch 11, 2026 | prnewswire.comOppenheimer downgrades Theravance Biopharma (TBPH)March 6, 2026 | msn.comTheravance considers possible sale after drug trial setbackMarch 4, 2026 | msn.comTheravance Biopharma Plummets As Phase 3 Study Falls ShortMarch 3, 2026 | benzinga.comThe Excruciating Failure That Could Cause Theravance, Down 27%, To Sell ItselfMarch 3, 2026 | investors.comTheravance Biopharma, Inc.: Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction ...March 3, 2026 | finanznachrichten.deTheravance Biopharma stock tumbles after trial failureMarch 3, 2026 | in.investing.comTheravance drops rare disease drug after late-stage trial setbackMarch 3, 2026 | seekingalpha.comTheravance Biopharma shares plunge 26% after drug trial failure triggers strategic reviewMarch 3, 2026 | proactiveinvestors.comTheravance plans strategic review, including possible sale, after drug trial failureMarch 3, 2026 | reuters.comTheravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction ActionsMarch 3, 2026 | prnewswire.comWhy Theravance Biopharma (TBPH) is a top momentum stock for the long termJanuary 6, 2026 | msn.comTheravance Biopharma, Inc. (TBPH) Discusses Ampreloxetine Phase 3 Program and Unmet Need in Neurogenic Orthostatic Hypotension with Multiple System Atrophy - SlideshowDecember 15, 2025 | seekingalpha.comTheravance Bio (TBPH) down 3.7% since last earnings report: Can it rebound?December 10, 2025 | msn.comTheravance Biopharma, Inc. (TBPH) Discusses Ampreloxetine Phase 3 Program and Unmet Need in Neurogenic Orthostatic Hypotension with Multiple System Atrophy TranscriptDecember 8, 2025 | seekingalpha.comTheravance Biopharma (TBPH) price target increased by 28.23% to 27.25December 7, 2025 | msn.comWhy Theravance Biopharma (TBPH) is a top growth stock for the long termDecember 5, 2025 | msn.comOppenheimer initiates coverage of Theravance Biopharma (TBPH) with outperform recommendationDecember 4, 2025 | msn.comTheravance Biopharma initiated with an Outperform at OppenheimerDecember 3, 2025 | msn.comBTIG Maintains Theravance Biopharma (TBPH) Buy RecommendationNovember 27, 2025 | msn.comTheravance Biopharma price target raised to $40 from $25 at BTIGNovember 26, 2025 | msn.comTheravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025November 20, 2025 | prnewswire.com Get Theravance Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TBPH Media Mentions By Week TBPH Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TBPH News Sentiment▼0.000.47▲Average Medical News Sentiment TBPH News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TBPH Articles This Week▼03▲TBPH Articles Average Week Get the Latest News and Ratings for TBPH and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Theravance Biopharma and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies ORKA News VKTX News ERAS News TWST News TNGX News RCUS News DNLI News TARS News DYN News BEAM News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TBPH) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theravance Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theravance Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
